Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + Famitinib + Irinotecan vs Irinotecan in Advanced Gastric Cancer
NCT07309185Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jul 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab, famitinib in gastric cancer (GC), sponsored by Shandong Cancer Hospital. Started Jul 2024; status: recruiting.
02
Drugs
adebrelimabfamitinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT07309185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07309185.